[en] The article presents a rapid and sensitive RP-HPLC method with UV detection, using the diclofenac sodium release determination in solid pharmaceutical formulations. A novel validation strategy based on accuracy profiles was used to select the most appropriate regression model with highest accuracy within well defined acceptance limits. Furthermore, the strategy was used to determine the limits of quantification as well as the suitable concentration range. The validation phase was completed by investigating of the risk profiles of various acceptable regression models in order to avoid obtaining measurements outside the acceptance limits fixed a priori. On the other hand, the present study shows how the LC method can be used more accurately to assess the kinetic dissolution profiles, instead the UV-visible method required by monographs of the USP. Robustness study was also performed in order to demonstrate the capability of this method to remain unaffected by a small and deliberate variation in method parameters. The LC method was validated using the total error approach, as a decision tool, guarantees that each of the future results that will be within the acceptance limits settled at ± 5 %. The UV spectrophotometric method based on the USP monograph, gives rise of impurities from diclofenac sodium in acidic condition (HCl 0.1 N). These impurities absorb at the same wave length (276 nm) as the active principal ingredient, which will yield some significant error in the per cent release during the dissolution test study. Described analytical method is a simple, sensitive, specific and more accurate indicating that this LC method is useful for manufacturing and quality control assay.
Research Center/Unit :
Centre Interfacultaire de Recherche du Médicament - CIRM
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Al-Kamarany, M.A.
El Karbane, M
Belomaria, M
Azougagh, M
Hubert, Philippe ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Alanazi, F
Cherrah, Y
Bouklouze, A
Language :
English
Title :
Development and Validation of LC Method for the Diclofenac Sodium Release Determination Using Accuracy Profile Concept
Alternative titles :
[en] Development and Validation of LC Method for the Diclofenac Sodium Release Determination Using Accuracy Profile Concept
D. W. Scholer, E. C. Ku, I. Boettcher and A. Schweizer, Am. J. Med., 80, 34 (1986).
European Pharmacopoeia (EP) 6.0, Diclofeanc Sodium Monograph, European Directorate for the Quality of Medicines-Council of Europe (COE) (2008).
Japanese Pharmacopoeia (JP), Diclofeanc Sodium Monograph, Society of Japanese Pharmac, edn. 15 (2006).
A. O. Santini, H. R. Pezza and L. Pezza, Talanta, 68, 636 (2006).
L. Hanysonava, M. Mokry, P. Kastner and J. Klimes, Chem Pap., 59, 103 (2005).
B. Mukherjee, S. Mahapatra, S. Das, G. Roy and S. Dey, Exp. Clin. Pharmacol., 28, 301 (2006).
R. Hájková, P. Solich, M Pospišilová and J. Šicha, Anal. Chim. Acta, 467, 91 (2002).
W. Thongchai, B. Liawruangrath, C. Thongpoon and T. Machan, Chiang Mai J. Sci. 33, 123 (2006).
L. G. Lala, P. M. D'Mello and S. R. Naik, J. Pharm. Biomed. Anal., 29, 539 (2002).
M. S. Aurora-Prado, M. Steppe, M. F. M. Tavares, E. R. M. Kedor-Hackmann and M. I. R. M. Santoro, JAOAC Int., 85, 333 (2002).
J. Wenrui and J. Zhang, J. Chromatog. A, 868, 101 (2000).
S. Mazurek and R. Szostak, J. Pharm. Biomed. Anal., 48, 814 (2008).
S. Mazurek and R. Szostak, J. Pharm. Biomed. Anal., 40, 1235 (2006).
B. Wang, G. Liu, Y. Dou, L. Liang, H. Zhang and Y. Ren, J. Pharm. Biomed. Anal., 50, 158 (2009).
J. Krzek and M. Starek, J. Pharm. Biomed. Anal., 28, 227 (2002).
M. Tubino and R. L. Souza, Talanta, 68, 776 (2006).
L. A. Carreira, M. Rizk, Y. El-Shabrawy, N. A. Zakhari and S. S. Toubar, J. Pharm. Biomed. Anal., 13, 1331 (1995).
S. Jawla and S. Jain, Int. J. Pharm. Sci. Drug Res., 2, 45 (2010).
J. Botello and G. P. Cabllero, Talanta, 42, 105 (1996).
J. R. Rackley, Dissolution Technol., 3, 12 (1996).
USP 32-NF 27, Diclofenac Sodium Delayed Release, Tablets, Unites State Pharmacopeia (USP), National Formulary, Unites States Pharmacopoeia Convention (2009).
D. Hoffman and R. Kringle, Pharm. Res., 24, 1157 (2007).
A. Bouabidi, E. Rozet, M. Fillet, E. Ziemons, E. Chapuzet, B. Mertens, R. Klinkenberg, A. Ceccato, M. Talbi, B. Streel, A. Bouklouze, B. Boulanger and Ph. Hubert, J. Chromatog. A, 1217, 3180 (2009).
FDA, Guidance for Industry: Analytical Procedures and Methods Validation, Center for Drug Evaluation and Research (CDER), US Dept. of Health and Human Services (2000).
FDA, Guidance for Industry Q9 Quality Risk Management, US Dept. of Health and Human Services, Food and Drugs Administration (2006).
International Conference on Harmonization of Technical Requirement for the Registration of Pharmaceuticals for Human Use Topic Q2 (R1): Validation of Analytical Procedures: Text and Methodology, Geneva (2005).
Ph. Hubert, J. J. Nguyen-Huu, B. Boulanger, E. Chapuzet, P. Chiap, N. Cohen, P. A. Compagnon, W. Dewe, M. Feinberg, M. Lallier, M. Laurentie, N. Mercier, G. Muzard, C. Nivet and L. Valat, STP Pharma Pratiques, 13, 101 (2003).
K. A. Shaikh, S. D. Patil and A. B. Devkhile, J. Pharm. Biomed. Anal., 48, 1481 (2008).
FDA, Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms, US Dept. of Health and Human Services, Food and Drugs Administration (1997).